Hugel aspires to become a global leading company, providing health and beauty to humanity and creating value for a happy life.
Hugel was first established in 2001, with a dream to enter the Korean botulinum toxin market.
By introducing "Botulax (Export brand: Letybo)", the botulinum toxin product developed over 10 years of R&D, into the domestic market, Hugel initiated its movement for company growth. Based on continuous R&D, Hugel expanded its portfolio by developing the HA filler "the Chaeum (Export brand: Dermalax, Revolax)" and its cosmetics brands "Wellage" and "PR4", fulfilling its company value of "New Hope, Better Life" as a strong partner in improving people’s lives and the value of happiness.
Hugel, continuously growing over the past 20 years, has become one of the leading companies in the domestic market from a startup company, writing a glorious new history. Botulax, celebrating the 10th anniversary of its launch in the domestic market last year, changed the paradigm of the domestic botulinum toxin market.
Becoming the no. 1 botulinum toxin product in 2016, it continues to lead the domestic market. HA filler "the Chaeum" has also celebrated its moment of glory by becoming the no. 1 product in the domestic market in 2019. Based on this, Hugel achieved annual revenue of KRW200bn in 2019 and is continuing its impressive growth as a total medical aesthetic company.
Hugel now aims to take a greater step forward beyond the domestic market into the global market. Last year, Hugel entered China by becoming the first Korean botulinum toxin to be approved, proving its product excellence and reliability. By continuously challenging into overseas markets such as Europe and the US, Hugel will promote the excellence of K-Bio in the international market and strive to become the global leading company in medical aesthetics.